Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PLYX vs SER: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SER Wins Head-to-Head Institutional Verdict (3–0 across 6 Pillars · 6–1 Matrix Metrics)

SER Overall Winner 6-Pillar Tally: PLYX 0 – 3 SER (3 Tie) Matrix Metrics: PLYX 1 – 6 SER

As of Nov 19, 2026, Serina Therapeutics, Inc. (SER) is the stronger overall head-to-head candidate over PLYX (PLYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLYX carries a Unified Composite Score of 43.3/100 (HOLD) at $1.51 (N/M Forward P/E, N/A operating margin), whereas SER carries 43.1/100 (HOLD) at $1.20 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: PLYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PLYX vs SER
PLYX US Equity
PLYX
Institutional Equity
$1.51
-6.21% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.43β · 60% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 33.0 Fund 52.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.0%), weak momentum, RSI 31
RSI-14: 31.3 · SMA20: $1.78 · SMA50: $1.93
SER NYSE American Head-to-Head Winner
Serina Therapeutics, Inc.
Pharmaceutical Preparations
$1.20
-11.11% 1D
Market Cap $35.9M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.40β · 98% Vol
Unified Composite Score
43.1 / 100 HOLD
Tech 25.0 Fund 57.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.9%), weak momentum, RSI 28
RSI-14: 28.3 · SMA20: $1.57 · SMA50: $1.84

6-Pillar Scorecard Institutional Category Breakdown (PLYX 0 – 3 SER)

Columns: Metric · PLYX · SER
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SER
Revenue Growth (YoY) N/A +154.9%
Earnings Growth (YoY) N/A -43.5%
TTM Revenue (USD) N/A N/A
Market Cap N/A $35.9M
3. Profitability & Quality SER
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -207.9%
4. Balance Sheet & Cash Flow SER
Cash Generation (TTM) N/A -$18M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $21M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PLYX (1) vs SER (6)
Institutional Metric PLYX SER Criterion Row Edge
Market Capitalization
Scale
N/A $35.9M Larger Scale SER
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +154.9% Higher Growth SER
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin SER
Net Profit Margin
Profitability
N/A 0.0% Higher Margin SER
Return on Equity (ROE)
Capital Efficiency
N/A -207.9% Higher ROE SER
52-Week Range Position
Momentum
0% ($2–$49) 2% ($1–$4) Stronger Trend SER
Beta / 30D Volatility
Risk Regime
1.43β · 60% Vol 1.40β · 98% Vol Lower Realized Risk PLYX
Unified Institutional Score
Composite Signal
43.3 / 100 (HOLD) 43.1 / 100 (HOLD) Higher Composite Tie
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$18M ($21M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLYX +10.04 pp
PLYX: -22.16% · SER: -32.2%
3M Horizon PLYX +31.14 pp
PLYX: -27.05% · SER: -58.19%
6M Horizon SER +25.27 pp
PLYX: -61.68% · SER: -36.41%
1Y Horizon SER +39.81 pp
PLYX: -95.69% · SER: -55.88%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLYX vs SER. Trailing 12-month operating profitability (PLYX N/A vs SER 0.0%) and valuation multiples (PLYX N/M vs SER N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PLYX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SER ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-207.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PLYX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLYX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SER UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PLYX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $35.9M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PLYX vs SER Key Questions & Quantitative Answers

As of Nov 19, 2026, Serina Therapeutics, Inc. (SER) is the stronger overall head-to-head candidate over PLYX (PLYX) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PLYX carries a Unified Composite Score of 43.3/100 (HOLD) at $1.51 (N/M Forward P/E, N/A operating margin), whereas SER carries 43.1/100 (HOLD) at $1.20 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: PLYX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.3); meanwhile SER is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SER leads the Growth & Scale pillar: PLYX posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SER at +154.9% YoY revenue growth and -43.5% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PLYX generates N/A in USD-normalized revenue versus N/A for SER. In operating R&D and SG&A reinvestment, PLYX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SER.

PLYX and SER trade at balanced relative valuation multiples. PLYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SER trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PLYX (N/A ROE) versus SER (-207.9% ROE) capital efficiency.

In options market volatility and institutional positioning, PLYX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.43β · 60% Vol realized risk). By comparison, SER carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.40β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.